May 20, 2021 – CorVent Medical (Santa Clara, CA) announced it has received CE Mark approval and is ready to launch commercial use of its RESPOND-19 Ventilator in Europe.
The novel system is designed for easy-to-use, flexible expansion of critical care ventilation capacity to allow hospitals to improve treatment of critically ill patients suffering from acute respiratory distress syndrome (ARDS).
Optimized for day-to-day clinical use and overflow ventilation needs, the system provides invasive and non-invasive respiratory support at a lower cost of ownership without the traditional requirements for costly service or maintenance plans.
The ICU-quality system includes mandatory, assist, and spontaneous ventilation modes along with built-in safeguards to meet individual patient’s needs, the company says. The streamlined, lightweight design simplifies training, ensures compatibility with all low flow oxygen sources, and allows for easy movement within the hospital.
In addition, the system filters out 99.9% of viral pathogens using antiviral safeguards. Optimized for a low cost of ownership, the system is ready to use out of the box from long-term storage without ongoing service contracts or costly maintenance.
In support of the company’s continued commercial growth, CorVent has appointed seasoned medtech financial executive, Travis Murphy, as chief financial officer (CFO). He joins the team after a successful tenure as CFO at Ativa Medical.